BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

408 related articles for article (PubMed ID: 25787859)

  • 1. Design, Synthesis and Biological Evaluation of Imidazo[1,2-a]pyridine Derivatives as Novel DPP-4 Inhibitors.
    Li Q; Zhou M; Han L; Cao Q; Wang X; Zhao L; Zhou J; Zhang H
    Chem Biol Drug Des; 2015 Oct; 86(4):849-56. PubMed ID: 25787859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis and anti-diabetic activity of triazolotriazine derivatives as dipeptidyl peptidase-4 (DPP-4) inhibitors.
    Patel BD; Bhadada SV; Ghate MD
    Bioorg Chem; 2017 Jun; 72():345-358. PubMed ID: 28302310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of 3H-imidazo[4,5-c]quinolin-4(5H)-ones as potent and selective dipeptidyl peptidase IV (DPP-4) inhibitors.
    Ikuma Y; Hochigai H; Kimura H; Nunami N; Kobayashi T; Uchiyama K; Furuta Y; Sakai M; Horiguchi M; Masui Y; Okazaki K; Sato Y; Nakahira H
    Bioorg Med Chem; 2012 Oct; 20(19):5864-83. PubMed ID: 22938786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and biological evaluation of triazole based uracil derivatives as novel DPP-4 inhibitors.
    Li Q; Han L; Zhang B; Zhou J; Zhang H
    Org Biomol Chem; 2016 Oct; 14(40):9598-9611. PubMed ID: 27714283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of triazole-based uracil derivatives bearing amide moieties as novel dipeptidyl peptidase-IV inhibitors.
    Deng X; Han L; Zhou J; Zhang H; Li Q
    Bioorg Chem; 2017 Dec; 75():357-367. PubMed ID: 29096096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapid generation of novel benzoic acid-based xanthine derivatives as highly potent, selective and long acting DPP-4 inhibitors: Scaffold-hopping and prodrug study.
    Li Q; Meng L; Zhou S; Deng X; Wang N; Ji Y; Peng Y; Xing J; Yao G
    Eur J Med Chem; 2019 Oct; 180():509-523. PubMed ID: 31336309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and biological evaluation of pyrrolidine-2-carbonitrile and 4-fluoropyrrolidine-2-carbonitrile derivatives as dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes.
    Wang J; Feng Y; Ji X; Deng G; Leng Y; Liu H
    Bioorg Med Chem; 2013 Dec; 21(23):7418-29. PubMed ID: 24153396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design of potent dipeptidyl peptidase IV (DPP-4) inhibitors by employing a strategy to form a salt bridge with Lys554.
    Maezaki H; Tawada M; Yamashita T; Banno Y; Miyamoto Y; Yamamoto Y; Ikedo K; Kosaka T; Tsubotani S; Tani A; Asakawa T; Suzuki N; Oi S
    Bioorg Med Chem Lett; 2017 Aug; 27(15):3565-3571. PubMed ID: 28579121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis and biological evaluation of novel pyrimidinedione derivatives as DPP-4 inhibitors.
    Li N; Wang LJ; Jiang B; Guo SJ; Li XQ; Chen XC; Luo J; Li C; Wang Y; Shi DY
    Bioorg Med Chem Lett; 2018 Jul; 28(12):2131-2135. PubMed ID: 29773502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis, biological evaluation, and docking studies of (s)-phenylalanine derivatives with a 2-cyanopyrrolidine moiety as potent dipeptidyl peptidase 4 inhibitors.
    Liu Y; Wu Y; Wu H; Tang L; Wu P; Liu T; Hu Y
    Chem Biol Drug Des; 2013 Aug; 82(2):140-6. PubMed ID: 23530834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent progress of the development of dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus.
    Li N; Wang LJ; Jiang B; Li XQ; Guo CL; Guo SJ; Shi DY
    Eur J Med Chem; 2018 May; 151():145-157. PubMed ID: 29609120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis and biological evaluation of hetero-aromatic moieties substituted pyrrole-2-carbonitrile derivatives as dipeptidyl peptidase IV inhibitors.
    Ji X; Su M; Wang J; Deng G; Deng S; Li Z; Tang C; Li J; Li J; Zhao L; Jiang H; Liu H
    Eur J Med Chem; 2014 Mar; 75():111-22. PubMed ID: 24531224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis, evaluation and molecular docking of thiazolopyrimidine derivatives as dipeptidyl peptidase IV inhibitors.
    Sharma M; Gupta M; Singh D; Kumar M; Kaur P
    Chem Biol Drug Des; 2012 Dec; 80(6):918-28. PubMed ID: 22943413
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Surrogating and redirection of pyrazolo[1,5-a]pyrimidin-7(4H)-one core, a novel class of potent and selective DPP-4 inhibitors.
    Deng X; Shen J; Zhu H; Xiao J; Sun R; Xie F; Lam C; Wang J; Qiao Y; Tavallaie MS; Hu Y; Du Y; Li J; Fu L; Jiang F
    Bioorg Med Chem; 2018 Feb; 26(4):903-912. PubMed ID: 29373269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Finding a Potential Dipeptidyl Peptidase-4 (DPP-4) Inhibitor for Type-2 Diabetes Treatment Based on Molecular Docking, Pharmacophore Generation, and Molecular Dynamics Simulation.
    Meduru H; Wang YT; Tsai JJ; Chen YC
    Int J Mol Sci; 2016 Jun; 17(6):. PubMed ID: 27304951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimization of the benzamide fragment targeting the S
    Deng X; Wang N; Meng L; Zhou S; Huang J; Xing J; He L; Jiang W; Li Q
    Bioorg Chem; 2020 Jan; 94():103366. PubMed ID: 31640932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of 3H-imidazo[4,5-c]quinolin-4(5H)-ones as potent and selective dipeptidyl peptidase IV (DPP-4) inhibitors: use of a carboxylate prodrug to improve bioavailability.
    Ikuma Y; Hochigai H; Kimura H; Nunami N; Kobayashi T; Uchiyama K; Umezome T; Sakurai Y; Sawada N; Tadano J; Sugaru E; Ono M; Hirose Y; Nakahira H
    Bioorg Med Chem; 2015 Feb; 23(4):779-90. PubMed ID: 25596166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis, biological screening, and molecular docking studies of piperazine-derived constrained inhibitors of DPP-IV for the treatment of type 2 diabetes.
    Kushwaha RN; Srivastava R; Mishra A; Rawat AK; Srivastava AK; Haq W; Katti SB
    Chem Biol Drug Des; 2015 Apr; 85(4):439-46. PubMed ID: 25216392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery and preclinical profile of teneligliptin (3-[(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl]thiazolidine): a highly potent, selective, long-lasting and orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
    Yoshida T; Akahoshi F; Sakashita H; Kitajima H; Nakamura M; Sonda S; Takeuchi M; Tanaka Y; Ueda N; Sekiguchi S; Ishige T; Shima K; Nabeno M; Abe Y; Anabuki J; Soejima A; Yoshida K; Takashina Y; Ishii S; Kiuchi S; Fukuda S; Tsutsumiuchi R; Kosaka K; Murozono T; Nakamaru Y; Utsumi H; Masutomi N; Kishida H; Miyaguchi I; Hayashi Y
    Bioorg Med Chem; 2012 Oct; 20(19):5705-19. PubMed ID: 22959556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of novel xanthine compounds targeting DPP-IV and GPR119 as anti-diabetic agents.
    Li G; Huan Y; Yuan B; Wang J; Jiang Q; Lin Z; Shen Z; Huang H
    Eur J Med Chem; 2016 Nov; 124():103-116. PubMed ID: 27560285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.